

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 47/42 // C07K 15/10</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/11799</b> <b>(43) International Publication Date:</b> 24 June 1993 (24.06.93)
<b>(21) International Application Number:</b> PCT/US92/09336 <b>(22) International Filing Date:</b> 9 November 1992 (09.11.92)  <b>(30) Priority data:</b> 810,593 18 December 1991 (18.12.91) US  <b>(60) Parent Application or Grant</b> (63) Related by Continuation US 810,593 (CON) Filed on 18 December 1991 (18.12.91)  <b>(71) Applicant (for all designated States except US):</b> PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).		<b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> AMIDON, Gordon, L. [US/US]; 2079 South 7th Street, Ann Arbor, MI 48103 (US). LEESMAN, Glen, D. [US/US]; 628 Peninsula Court, Ann Arbor, MI 48105-2506 (US). SINKO, Pa- trick, J. [US/US]; 64 Minnehaha Boulevard, Oakland, NJ 07436 (US).  <b>(74) Agents:</b> RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).  <b>(81) Designated States:</b> AU, CA, FI, HU, JP, KR, NO, US, Eu- ropean patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> SOYBEAN PROTEIN OR HYDROLYZATES IN PHARMACEUTICAL COMPOSITIONS TO PROTECT BI- OACTIVE PEPTIDES FROM ENZYMATIC INACTIVATION  <b>(57) Abstract</b>  Proteins or peptidic substances, which may be prepared from naturally occurring proteins, enhance the bioavailability of proteolytically-labile therapeutic agents which, in the absence of the protein or peptidic substance would suffer enzymatic inacti- vation upon administration.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

# SOYBEAN PROTEIN OR HYDROLYZATES IN PHARMACEUTICAL COMPOSITIONS TO PROTECT BIOACTIVE PEPTIDES FROM ENZYMATIC INACTIVATION.

This invention relates to enhancing the bioavailability of proteolytically labile therapeutic agents by administering the therapeutic agent in combination with a protecting agent comprising a protein, a purified natural protein, a molecular weight  
10 fractionated protein, or a partially hydrolyzed protein.

## Background of the Invention

Peptide drugs and drugs containing a peptidase labile bond are among the most promising medicinal agents of modern times, but their instability in the presence of proteolytic enzymes in the gastrointestinal tract and other mucosal tissues usually  
15 requires that they be administered parenterally. Although patients can be taught to inject parenterally, there has been a long felt need to develop a non-invasive method for self administration of peptide drugs.

Protease inhibitors and penetration enhancers are means often considered to circumvent the enzymatic and penetration barriers to peptide and protein absorption  
20 from mucosal routes of administration. Because of such barriers, the bioavailability of peptide and protein drugs from mucosal routes is poor.

Non-parenteral administration of peptide drugs in particular often results in very low bioavailability because of hydrolysis of the peptides by proteolytic enzymes. For leuprolide, this ranges from 0.05% following oral administration to 38% following vaginal  
25 administration; for insulin, the corresponding figures are 0.05% and 18%. Lee, Journal of Controlled Release, 13, 213 (1990).

Examples of proteolytic enzymes which inactivate proteolytically-labile therapeutic agents are pepsin, trypsin, chymotrypsin, elastase, and carboxypeptidase in the intestinal lumen, and the aminopeptidases located on the mucosal surfaces of  
30 the GI tract, nose, and vagina.

Transport of intact oligopeptides across adult mammalian jejunum has been demonstrated *in vitro* and *in vivo* as well as in combination with peptidase inhibitors. Friedman and Amidon, Pharmaceutical Research 8, no. 1, P. 93, (1991).

Fujii et al; US 4,639,435 (1987) claims the use of 1-isopropyl-4-[4-(1,2,3,4-  
35 tetrahydronaphthoxy)benzoyl] piperazine methanesulfonate as an inhibitor of chymotrypsin to be co-dosed orally or rectally with a chymotrypsin-labile drug (kallikrein

-2-

or calcitonin). The reference also discloses the use of benzoylpiperazine esters for this purpose. The reference does not describe the mechanism of these inhibitors.

Cho and Flynn; International Patent Application WO-90/03164 (1990) disclose the use of protease inhibitors in oral formulation but do not describe the nature of such inhibitors in detail; the only protease inhibitor which appears in the examples is aprotinin.

Kidron, et al; US 4,579,730 (1986) disclose the use of protease inhibitors in oral formulation of insulin. Soybean flour is disclosed as a source of soybean trypsin inhibitor (Bowman-Birk trypsin/chymotrypsin inhibitor; molecular weight 8000 daltons).

10 Ziv, et al; Biochem. Pharmacol. 36, 1035-1039 (1987) disclose the use of the protease inhibitor aprotinin to enhance the oral absorption of proteins.

Losse, et al; East German Patent DD 252 539 A1 (1987) disclose the use of epsilon-aminocaproic acid and aprotinin as protease inhibitors in oral formulation of peptides.

15 Lee; J.; Controlled Release 13, 213-223 (1990) reviews the use of protease inhibitors in formulations of peptides for oral, nasal, buccal, rectal, vaginal, pulmonary, and ocular routes.

Certain small peptides containing up to four amino acids have been shown to enhance the bioavailability of peptide drugs.

20 Hussain, et al, Biochemical and Biophysical Research Communications, 133, no. 3, 923 (1985) suggested that nasal administration of peptides may become an important route provided that peptidases in the nasal mucosa can be transiently inhibited via coadministration of pharmacologically inactive peptidase substrates.

Faraj, et al, Journal of Pharmaceutical Sciences 79, no. 8, 698 (1990) showed 25 that in the presence of the small peptides, L-tyrosyl-L-tyrosine and tri-L-tyrosine methyl ester, the hydrolysis of leucine enkephalin was reduced, suggesting that competitive inhibition of nasal peptidases was caused by these small peptides.

Friedman and Amidon, supra, demonstrated that coprefusion of the tripeptide YGG with enkephalin (YGGFL) resulted in increased absorption of YGGFL in a perfused 30 rat intestine.

Hori et al; J. Pharm. Sci. 72, 435-439 (1983), disclose the use of various amino-protected peptides to protect insulin from degradation when injected subcutaneously. The peptides used were benzyloxycarbonyl-Gly-Pro-Leu-Gly, benzyloxycarbonyl-Gly-Pro-

-3-

Leu, dinitrophenyl-Pro-Leu-Gly, and benzyloxycarbonyl-Gly-Pro. Numerous publications disclose enzymatic treatment of vegetable proteins. An early U.S. Patent No. by John R. Turner (2,489,208) discloses a pepsin modified whipping agent component. An alkaline material such as sodium sulfite, sodium carbonate or sodium hydroxide is used to extract glycinin at a pH 6.4-6.8. The glycinin is then precipitated from the extract (e.g., pH 4.2-4.6) at its isoelectric pH in which sulfur dioxide may be utilized as the adjusting acid. The precipitated glycinin product is then modified with pepsin under temperature and pH conditions conducive to hydrolysis of protein. The glycinin is hydrolyzed with pepsin until its water-solubility is increased to 40-50%. Similarly, U.S. Patent No. 2,502,482 by Sair et al. reports the enzymatic modification of glycinin with pepsin to produce an isolate wherein at least 60% by weight of the pepsin modified isolate is water-soluble at a pH 5.0.

Puski reports the enzymatic modifying of soy isolates (precipitated at pH 4.5) with *Aspergillus oryzae* in "Modification of Functional Properties of Soy Proteins by Proteolytic Enzyme Treatment" (Cereal Chem. 52, pages 655-665 (1975)).

Several publications also report using saline solutions to extract soy proteins. A publication by A. K. Smith et al. (Jr. American Chemical Society, Vol. 60, June 1938, pages 1316-1320) reports the extraction of soybean meal with pH 6.7 water alone yields more protein extract than an aqueous extraction in the presence of neutral salts.

U.S. Patent No. 4,131,607 by Petit discloses a two-stage alkaline extraction. The extraction is initially conducted in the presence of sodium sulphite and magnesium salt at a pH 7.0-8.5 which is then increased to a pH 10.0-10.5 to complete the extraction. The protein extracts are then precipitated or curded by adjusting the extract to a pH 4.5-5.5. A patent issued to Martinez et al. (U.S. Patent No. 3,579,496) similarly discloses a multiple solvent extraction process.

#### Summary of the Invention

We have found that proteins, peptides, purified natural proteins, and filtered, solvent-extracted, molecular weight-fractionated or partially hydrolyzed proteins hereinafter referred to as protecting agents enhance the oral, nasal, rectal and vaginal bioavailability of proteolytically-labile therapeutic agents which, in the absence of the protecting agents, would suffer enzymatic inactivation upon attempted oral, nasal, rectal or vaginal administration.

### Detailed Description of the Invention

This invention comprises a protecting agent and a pharmaceutically effective amount of a proteolytically-labile therapeutic agent, with the proviso that when said protecting agent is soy flour said therapeutic agent may not be insulin.

5 In another aspect this invention comprises a method of enhancing bioavailability of a proteolytically-labile therapeutic agent to a mammal or other animal in need of said therapeutic agent comprising administering said therapeutic agent in combination with a bioavailability enhancing amount of protecting agent with the proviso that when said protecting agent is soy flour said therapeutic agent may not be insulin.

10 A proteolytically-labile therapeutic agent, which is an active ingredient in a pharmaceutical composition of the invention, includes those which possess peptide bonds in their structure or which, upon exposure to various proteolytic enzymes present in the digestive tract or nasal or vaginal mucosa, are inactivated by decomposition, denaturation or other means. When administered orally, nasally, rectally or vaginally,  
15 therefore, the active therapeutic agents cannot be absorbed or cannot produce their therapeutic effects to a satisfactory extent.

Examples of such proteolytically-labile therapeutic agents are peptides, such as calcitonin, prolactin, adrenocorticotropin, thyrotropin, growth hormone, gonadotropic hormone, oxytocin, vasopressin, gastrin, tetragastrin, pentagastrin, glucagon, secretin,  
20 pancreozymin, substance P and gonadotropin. Other examples of proteolytically-labile therapeutic agents are luteinizing releasing hormone, leuprolide, enkephalin, follicle stimulating hormone, cholecystikinin, thymopentin, endothelin, neurotensin, interferon, interleukins, insulin, and insulinotropin. Other examples are therapeutic antibodies, such as those used to treat septic shock.

25 As the proteolytically-labile therapeutic agents, there may also be used purified extracts of natural origin and their chemical modifications as well as products obtained by tissue culture and products obtained by cultivating microorganisms or cells rendered productive by genetic engineering techniques. The proteolytically-labile therapeutic agents may also include synthetic peptides and derivatized synthetic peptides such as  
30 Terlakiren[isopropyl-N-[N-(4-morpholine-carbonyl)-L-phenylalanine-S-methyl-cysteine]-2(R)-hydroxy-3(S)-amino-4-cyclohexylbutanoate) (US Patent No. 4,814,342).

Protecting agents of the present invention may be chemically synthesized proteins and peptides, natural proteins, purified natural proteins, chemically modified



-5-

natural proteins or partially hydrolyzed natural proteins, or proteins which have been fractionated according to molecular weight, polarity, or charge, or mixtures thereof. Natural, food-grade proteins or partially hydrolyzed food-grade proteins are preferred. The molecular weight of the protecting agent should be greater than 1000.

5       The procedures for molecular weight fractionation of the protecting agent may be varied to produce any desired molecular weight fraction of a natural protein. Solvent extraction may be used to separate proteins according to molecular weight, polarity or charge. Enzymatic or chemical hydrolysis of a protein may be followed by separation of the desired molecular weight fraction by ultrafiltration membranes or dialysis  
10       membranes. Molecular weight fractionation may also be effected by gel chromatography or other means.

Hydrolysis of proteins or peptides may be carried out by heat treatment, or by treatment with acid or base or cyanogen bromide or by other chemical means.

Enzymatic treatment may be carried out with a single proteolytic enzyme, or with  
15       various combinations of proteolytic enzymes, acting concurrently or sequentially. A variety of proteolytic enzymes may be used, including but not limited to trypsin, chymotrypsin, elastase, carboxypeptidase, aminopeptidase, pepsin, and collagenas .

Fractionation and enzymatic treatments to produce the protecting agents of this invention may be applied to a wide variety of proteinaceous materials. Naturally  
20       occurring proteins of animal or vegetable origin are preferred. Such proteinaceous starting materials include but are not limited to soy flour, soy protein, wheat gluten, almond powder, peanut powder, casein, fish protein, and the like.

Without intending to be limited thereby, it is believed that the protecting agents of this invention function as sacrificial protease inhibitors which thereby enhance the  
25       bioavailability of pharmaceutical agents that are labile to certain proteases that can degrade the pharmaceutical agents upon oral, nasal, vaginal or rectal administration. Coadministration of these protecting agents with the labile pharmaceutical agents results in (1) competitive occupancy of the degrading proteases by said protecting agents, (2) inhibition of protease degradation of the pharmaceutical agents resulting in  
30       enhanced absorption and therapeutic effectiveness, and (3) ultimate metabolism and absorption of the protecting agents.

In view of the above-proposed mechanism of action it is believed to be desirable to match the dissolution rate of the protecting agent to the dissolution rate of the

proteolytically-labile therapeutic agent. Generally, we have found that short dissolution times of the protecting agent are more effective for low molecular weight therapeutic agents. Peptides ranging in molecular weight of  $>1000$  to  $<100,000$  are preferred, with a molecular weight of  $>1000$  to  $<30,000$  being especially preferred.

5           The effective protecting agent fraction must be matched to the particular lability characteristics of the proteolytically-labile therapeutic agent. Thus, for a therapeutic agent which possesses aminopeptidase lability, a protecting agent fraction which has a fast dissolution rate and is effective against aminopeptidase is preferred. For the aminopeptidase-labile therapeutic agent D-Ala-D-Leu-enkephalin (YdAGFdL), a  
10 preferred protecting agent is the  $<30,000$  MW fraction of pepsin-treated decanted soy flour, as demonstrated in Example 15. In general, for a proteolytically-labile therapeutic agent possessing lability to one or more luminal or mucosal proteases, a preferred protecting agent is one which improves the systemic bioavailability of the therapeutic agent when the protecting agent is dosed at a practical total dose, as described above.  
15 Preferred protecting agent fractions, for a particular proteolytically-labile therapeutic agent, are obtained by the decanting, filtration, extraction, hydrolysis, and size fractionation processes described herein. Preferred protecting agent fractions for a particular proteolytically-labile therapeutic agent are identified utilizing *in vitro* and *in vivo* procedures such as those exemplified herein.

20           The pharmaceutical composition according to the present invention is preferably administered to a mammal or other animal in need of such treatment in any form in which a protecting agent and proteolytically-labile therapeutic agent are allowed to coexist in the intestine, for example, in the form of tablets, granules or capsules, with both ingredients provided with an enteric coating either separately or compositely. The  
25 composition may also be administered rectally or vaginally in the form of suppositories prepared by adding both ingredients to a suppository base in ordinary use. Likewise, the protecting agent and proteolytically-labile therapeutic agent may be dosed together in a nasal spray. Where desirable, these dosage forms may be added with various pharmaceutically acceptable additives such as excipients and emulsifiers.

30           The dose of the proteolytically labile therapeutic agent is preferably 0.0001 to 1 times the dose if such substance is administered orally in the prior art. The amount of the protecting agent will depend upon the route of administration, the lability of the therapeutic agent, and the dose of the therapeutic agent. For oral, rectal, and vaginal

-7-

administration, the protecting agent will generally be dosed at about 10-1500 mg. In the case of orally-dosed solutions or suspensions, the protecting agent will be dosed at 10 mg to about 15 gm. For nasal administration, the dose of protecting agent will be generally lower, in the range about 1-100 mg.

5        Several pharmaceutical compositions for intestinal absorption according to this invention were evaluated with respect to their effectiveness, with the results given below.

The following examples are intended only to further illustrate the invention and are not intended to limit the scope of the invention which is defined by the claims.

10

#### EXAMPLE 1

Processing of Commercial Proteins and Flours.  
Fractionation by Solubilization.

15

##### Soy Flour.

Soy Flour (from Sigma Chem. Co.), 4.5 g in 135 ml 0.01M pH 7.5 phosphat buffer and 15 ml 0.05% Thimerosal was stirred for 15 minutes, sonicated for 10 minutes and agitated for 25 hours at room temperature. The mixture was allowed to settle, the supernatant drawn off, centrifuged, and filtered. In this way the directly-soluble fraction  
20        was obtained for recovery and use or further processing.

#### EXAMPLE 2

25

Processing Of Commercial Proteins and Flours.  
Molecular Weight Fractionation by Solubilization  
and Dialysis. Soy Flour

The procedure of Example 1 was followed to prepare a solution of decanted and filtered soy flour which was processed further as follows to achieve molecular weight (MW) discrimination. The solubilized fraction was evaporated to dryness at 55°C in a vacuum oven. The evaporate was dissolved in water and dialyzed in 1000 Molecular Weight Cut-Off (MWCO) Spectrum dialysis tubing against water over a period of 24  
30        hours with periodic changes of dialysing medium. The retentates were evaporated giving 1.17g of a >1000 MW solubilized soy flour fraction.

35

-8-

EXAMPLE 3

Processing of Commercial Proteins and Flours.  
Molecular Weight Fractionation by  
Solubilization and Ultrafiltration (UF):  
1K-30K and 30K-100K Fraction.

Commercial Soy Flour, Sigma No. S-9633 (288 g) was added with stirring to a solution of 8640 ml of an 0.01M pH 7.5 phosphate buffer and 1920 ml of 0.1% Thimerosal. The suspension was mixed for an additional 15 minutes with a magnetic stirrer. The mixture was then sonicated for 10 minutes and then stirred at room temperature for 24 hours. The solution was then centrifuged at 2500-3000 rpm for 1 hour. The supernatant liquid was separated by ultrafiltration using a 100K Nominal Molecular Weight Limit Pellicon (Millipore Corp., Bedford, MA) Membrane. The retentate (>100K) was discarded, and the permeate (<100K) was separated using a 30K nominal molecular weight Pellicon membrane. The second (30K-100K) was saved, and the second permeate was separated on a 1K nominal molecular weight Pellicon membrane. The third retentate (1K-30K) was saved, and the third permeate (<1K) was discarded. The 1K-30K fraction was freeze-dried, and the 30K-100K fraction was dried in a vacuum oven. The yield of the 1K-30K fraction (7.33 g) was 2.5% of the starting soy flour. The yield of the 30K-100K fraction (5.25 g) was 1.8% of the starting soy flour.

EXAMPLE 4

Processing of Commercial Proteins and Flours.  
Hydrolysis by Pepsin and Molecular Weight Fractionation  
by Dialysis. Soy Flour

Soy flour was hydrolysed into lower molecular weight (MW) fragments using pepsin and the hydrolysate was fractionated into 1000-3500, 3500-6/8K and 6/8K-12/14K MW fractions according to the following procedure.

Soy flour (Sigma # S-99633; 5.4 g) and Thimerosal (50 ppm in final concentration) were added to 180 ml of a solution containing pH 1.9 0.2N KCl/0.2 N HCl and mixed for one-half hour after which Pepsin (Sigma #P-6887; 18.0 mg) was added. Aliquots of 20 ml each were placed in each of 9 pieces of 12,000-14,000 Molecular Weight Cut-Off (MWCO) Spectrum dialysis tubing, and were dialyzed against 55 ml of pH 1.9 KCl buffer at 37°C in a shaking water bath. The buffer was changed after 2


-9-

hours and after 6 hours and dialysis was continued for 24 hours. Permeates (<12/14K) from each time period were combined and evaporated at 55°C in a vacuum oven.

The 2, 6 and 24 hour samples were placed in 1000 MWCO tubing and dialyzed against water. The resulting retentates (1K-12/14K) were evaporated at 55°C in a vacuum oven, giving a total weight of 449.5 mg; 418 mg of this material was dissolved in 30 ml deionized water and placed in two pieces of 3500 MWCO dialysis tubing, and dialyzed against 55 ml water at room temperature for 24 hours. The water was changed after 2, 6 and 24 hours dialysis, and the permeates (1K-3.5K) were combined and evaporated at 55°C in a vacuum oven.

The retentates from each piece of tubing were each placed in 6000/8000 MWCO tubing and treated as above. Evaporation of the permeates provided fragments of 3500-6000/8000 MW. The retentates, representing the 6000/8000-12000/14000 MW fraction, were also combined and evaporated. Scheme I summarizes the described fractionation procedure.

#### SCHEME I



-10-

EXAMPLE 5

Processing of Proteins and Flours. Treatment  
with immobilized Pepsin.

5 Soy flour (Sigma Chem. Co.; S-9633) was processed as in Example 1, and was dried. This material was ultrafiltered with a 30K MWCO membrane. The retentat (>30K) was collected and dried. 13.8 g of this material was dissolved in 900 ml water, and the pH was adjusted to pH 2.0 with 0.1 N HCl. 1.19 g Immobilized pepsin (immobilized on 4% cross-linked beaded agarose Sigma Chemical Co.; P-3286; 40  
10 units/mg) was added. This suspension, maintained at 37°C, was ultrafiltered through three 30K MWCO membranes. The permeate (<30K) was collected in 15 minut intervals and was freeze-dried. The retentate (>30K) was recycled through ultrafiltration processing. The products of pepsin hydrolysis appear in the permeate. Table I presents the volume of each permeate fraction, and the mass  
15 of hydrolyzed peptide in each dried fraction.

Table I. Yield of pepsin hydrolyzed peptides, obtained through the methods described in Example 5.

20	Collection Time (min)	Volume (ml)	Mass Collected (mg)
	15	600	361.1
	30	300	385.0
	45	300	341.5
25	60	300	361.3
	75	275	403.2
	90	350	390.1
	105	500	557.8
	120	600	410.5
30	135	550	261.6

-11-

EXAMPLE 6

Processing of Commercial Proteins and Flours.  
Hydrolysis by Sequential Enzyme Treatments.

Trypsin and Elastase. Soy Flour

5

Soy flour (600 mg) was dispersed in 20 ml 0.01M potassium phosphate buffer, pH 7.5 with 50 ppm Thimerosal. 2 Mg of trypsin was added and the mixture was placed in 12/14K MWCO dialysis tubing. The mixture was dialysed against 50 ml of buffer at 37°C in a shaking water bath. The buffer was changed after 2 hours and 6  
10 hours and the dialysis continued for 24 hours. 50 ppm Thimerosal was added to the 6 hour buffer. This procedure was carried out in triplicate.

The 2, 6 and 24 hour permeate samples for each of the triplicate dialysis samples were combined, absorbance at 280 nm determined and the samples evaporated in a 55°C vacuum oven. The three evaporation residues were reconstituted  
15 with 20 ml deionized water, 50 ppm in Thimerosal.

2.0 mg of elastase (0.182 ml of elastase solution, 11 mg protein/ml) was added to each and the samples were placed in 12/14K MWCO dialysis tubing and dialysed against buffer. The buffer was changed after 6 hours and dialysis was continued for 24 hours. After determining absorbance at 280 nm, the permeates were evaporated as  
20 described above.

Material so-obtained was designated as sequentially-treated trypsin/elastase soy, MW <12/14K.

EXAMPLE 7

25

Enhancement of Terlakiren Oral Absorption by  
Protecting Agents in Dogs

Renin antagonist tripeptide terlakiren (200 mg of solid crystalline drug powder in a hard gelatin capsule formulation) was coadministered to four fasted Beagle dogs with an aqueous slurry of 1 g of the test inhibitor in 150 ml water. Serum levels of  
30 tripeptide were measured at 6 time points post-dose: 15 min, 30 min, 1 hr, 2 hr, 3 hr and 4 hr. Four fasted dogs were used for each study, each serving as its own control on a preceding week. Serum was extracted with N-butyl chloride followed by incubation with an aqueous solution of chymotrypsin. The degradation product was assayed, after derivitization with fluorescamine. The fluorescence detector was a Kratos  
35 Spectroflow 280. The column was a Waters Novapak C-18. The emission wavelength

-12-

was 380 nm. The mobile phase was 75:25 water:acetonitrile and flow rate 1.0 ml/min. The detection limit was 10 ng/ml. Zero-to-four-hour areas under curves (AUCs) were calculated from the concentration-vs-time plots for each dog using the trapezoidal rule.

Table II demonstrates that commercially available soy protein (PP 620 from Protein Technologies Inc.) and a 1-30K fraction of processed soy flour (prepared as in Example 3) enhance the oral bioavailability of terlakerin, a chymotrypsin-labile therapeutic agent.

10

15

20

TABLE II					
Area under the plasma level vs. time curve (AUC) for dogs					
AUC ( $\mu\text{g-hr/ml}$ )					
Dog #					
Formulation	34112	34101	04132	04094	Mean
PP620	0.863	0.436	0.117	0.417	0.458
Soy (1-30K)	0.420	0.320	0.078	0.326	0.286
Control	0.043	0.026	0.022	0.106	0.049
Ratio: PP620/Control	20.1	16.8	5.3	3.9	11.5
Soy (1-30K) /Control	9.8	12.3	3.5	3.1	7.2

#### EXAMPLE 8

##### Protection from Chymotrypsin Degradation of Terlakerin: In Vitro Methodology

25

A standard procedure was employed to assess the in vitro inhibitory potency of various proteins and processed products thereof vs the chymotrypsin degradation of terlakerin, as follows. Test solutions of alpha-chymotrysin ( $0.67 \times 10^{-7}\text{M}$ ), terlakerin (0.065 mM) and the test inhibitor (at concentrations of about 0.1 to/or 0.5 mg/ml) were prepared in a pH 6.5 citric acid (0.10 M)/disodium phosphate (0.20M) buffer at a final



-13-

buffer concentration of 300 mOsm and incubated 37°C. Samples were taken at times 0 and then at 5 minute intervals, quenched with HCl to pH 2.0 preparatory to HPLC analysis. HPLC analysis of terlakiren was carried out using a Waters Resolve 5u C-18 column. The mobile phase was a water:acetonitrile (50:50) mixture to which was added 1 ml of phosphoric acid per liter. Data was expressed as % inhibition of terlakiren degradation based on comparison with time 0 control value, as calculated from the following equation:

$$\% \text{ inhibition} = 100 \times [1 - k_{inh}/k_c]$$

where  $k_{inh}$  is the initial degradation rate of terlakiren in the presence of the protecting agents and  $k_c$  is the initial degradation rate of terlakiren without protecting agents.

% Inhibitions were determined on decanted, ultrafiltered soy flour, 1K-30K fraction, as shown in Table III.

TABLE III		
Reduction of chymotrypsin - catalyzed degradation of terlakiren by the 1-30K fraction of decanted, ultrafiltered soy flour		
Inhibitor Concentration (mg/ml)	Inhibitor Concentration* (mg protein/ml)	% Inhibition
0.5	0.04905	75.4
0.25	0.02453	79.8
0.1	0.00981	21.5
0.05	0.00491	29.3
0.01	0.00098	4.8

\*Corrected for protein content.

-14-

**EXAMPLE 9**

**$\alpha$ -Chymotrypsin Hydrolysis of Terlakiren**  
**Methodology to Determine  $K_i$  Values of Inhibitors**

$K_i$  is defined as the inhibition Michaelis-Menton constant - a conventional measure of the affinity of an inhibitor for the active site and, hence, its potency as an inhibitor of the enzyme.  $K_i$  determinations can be carried out from the initial degradation rate data acquired at several concentrations of inhibitor at constant substrate and enzyme concentrations. Initial rates are expressed as millimoles terlakiren degraded per minute, as shown in Table IV.

<b>TABLE IV</b> <b>Reduction of chymotrypsin-catalyzed degradation</b> <b>of Terlakiren by 1K-30K Decanted</b> <b>and Ultrafiltered Soy Flour</b>		
Inhibitor Concentration (mg/ml)	Inhibitor Concentration** (mg protein/ml)	$k^*$ (m mol/min)
0.5	0.04905	$1.93 \times 10^{-4}$
0.25	0.02453	$1.59 \times 10^{-4}$
0.1	0.00981	$6.17 \times 10^{-4}$
0.05	0.00491	$5.56 \times 10^{-4}$
0.01	0.00098	$7.48 \times 10^{-4}$
Pooled control		$7.86 \times 10^{-4}$
* Initial rate loss of Terlakiren ** Corrected for protein content.		

Alternatively, determination of  $K_i$  for a single inhibitor concentration ("single-point  $K_i$ ") can be carried out using the standard Michaelis-Menton equation for competitive inhibition. Determination of  $K_i$  for multiple concentrations ("multiple-point  $K_i$ ") can be

-15-

carried out using the same relationship, fitting the data to the equation using nonlinear regression analysis.

#### EXAMPLE 10

5        The dissolution time is an important factor for the performance of the protecting agents of this invention. For the purpose of this disclosure, the reported dissolution time is the time required for a 0.5 mg/ml slurry of the test solid to dissolve completely in a 0.1M citric acid/0.2M disodium phosphate pH 7 buffer at room temperature rotating end over end at 8 rpm. Visual inspection was used to determine the endpoint for  
10    complete dissolution.

#### EXAMPLE 11

      The % protein was determined for various materials which are protecting agents. The concentrations of carbon, hydrogen, and nitrogen in the sample were determined  
15    using a Perkin-Elmer 2400 C, H, and N Elemental Analyzer. Approximately two mg of sample was accurately weighed and placed into the analyzer. The % nitrogen in the sample was multiplied by 6.25 to give the estimate of % protein.

#### EXAMPLE 12

20        The ability of a variety of commercial and processed protein fractions to reduce the degradation of terlakiren by chymotrypsin was determined. Soy flour was from Sigma Chem. Co.; almond flour and peanut flour were from Pert Labs; wheat gluten was from Total Foods Corp.

      Soy flour from Sigma Chemical Co. is unroasted, and thus contains active Bowman-Birk trypsin/chymotrypsin inhibitor, which has an 8000 MW.  
25

      Soy protein (#PP620) from Protein Technologies, Inc. is a heat-treated preparation, in which the Bowman-Birk trypsin/chymotrypsin inhibitor has been inactivated. Percent inhibition was determined as described in Example 8. Table V demonstrates that the tested protecting agent fractions reduce the chymotrypsin-catalyzed degradation of terlakiren, a chymotrypsin-sensitive renin inhibitor.  
30

-16-

TABLE V	
In vitro Inhibition of Degradation of Terlakiren by Commercial and Processed Proteins (0.5 mg/ml)	
Material Source/Description	% Inhibition (according to Example 8)
1. Soy flour, pepsin-treated and dialysed (>1K)	87
2. Soy flour, pepsin-treated and fractionated (Example 4)	
1000-3500 MW	24.0
3500-6/8K MW	46.6
6/8K-12/14K MW	85.1
3. Soy Flour	69.9
4. Soy flour, decanted and ultrafiltered 1K-30K MW	
30K-100K MW	75.4 and 93.3 (two preparations) 75.4 and 86.8 (two preparations)
5. Soy Flour, >1000 MW dialysis	97.6
6. Wheat gluten, decanted and ultrafiltered 1K-30K MW	95.8
7. Wheat Gluten	76.8
8. Peanut flour, decanted and ultrafiltered 1K-30K MW	28.6
9. Almond flour, decanted and ultrafiltered 1K-30K MW	37.6
10. Soy Protein (Protein Tech., Inc.)	86.0

EXAMPLE 13

For a variety of commercially available protein materials and for processed protein fractions, the % protein, dissolution time, and  $K_i$  were determined (as described in Examples 11, 10, and 9, respectively). These data are presented in Table VI. These data demonstrate that degradation-reducing fractions can be prepared which exhibit both a low  $K_i$  and a short dissolution time.

Soy flour from Sigma Chemical Co. is unroasted, and thus contains active Bowman-Birk trypsin/chymotrypsin inhibitor, which has an 8000 MW.

-17-

5

10

15

20

25

TABLE VI			
Dissolution Rate and Inhibition Constants of Representative Commercial and Processed Protein			
Material Source/Description	% Protein	Dissolution Time	Determined Ki
A. Commercial Proteins/Flours			
1. Casein (Sigma C-5890)	87.94	> 4 days	0.240*
2. Soy Flour	51.69	> 4 days	0.18*
3. Wheat Gluten	78.81	> 4 days	0.091*
B. Ultrafiltered (1K-30K) Substances			
1. Soy Flour	9.81	0.1 min	0.00765
2. Almond Flour	10.37	2.3 min	0.0618*
3. Casein	71.31	1.8 min	—
4. Peanut Flour	13.19	3.1 min	0.120*
5. Wheat Gluten	37.81	3.8 min	0.0060*
C. Ultrafiltered (30K-100K) Substances			
1. Soy Flour	44.44	2.6 min	0.0029
D. Dialysis, >1K			
1. Soy Flour	76.5	> 4 days	0.010
E. Ultrafiltered, Pepsin-Treated (<30K)			
1. Soy Flour (Ex. 16)	80.1	0.1 min	0.0094
* single-point Ki estimation (concentration of inhibitor 0.5 mg/ml)			

EXAMPLE 14

30

Rabbit Intestinal Brush Border Membrane Vesicle  
(BBMV) Enzymatic Degradation of Cholecystokinin-8 (CCK-8).  
Inhibition by Soy Protein Fractions.

35

Rat jejunal brush border membrane vesicles (BBMV) were prepared according to the method of Kessler et al (Biochem. Biophys. Acta 506 (1978) 136). BBMV (25

-18-

microgm protein) were incubated with CCK-8 (10 micromolar) in the presence and absence of protecting agents (0.15 mg/ml) in a total volume of 1 ml, at 37°C. Samples were withdrawn at 1 and 3 minutes, were quenched by acetonitrile in an ice bath, and were assayed for undegraded CCK-8 using a high performance liquid chromatography assay. Data presented in Table VII demonstrate that two different molecular weight fractions of processed soy protein were active as inhibitors of the degradation of CCK-8 by BBMV proteases, presumably aminopeptidases.

Table VII. Degradation of CCK-8 by BBMV protease. Effect of fractionated soy protein.

Incubation Time (min)	%CCK-8 Remaining		
	1K-30K MW 30K-100K MW		
	No inhibitor	Inhibitor	Inhibitor
1 min	42%	59%	67%
3 min	8%	10%	16%

#### EXAMPLE 15

##### Protection against degradation by aminopeptidase in vivo.

The pentapeptide enkephalin analogue D-Ala-D-Leu-enkephalin (YdAGFdL) (1.0 mg) was directly ileally dosed to chronically ileally fistulated rats. Radiolabeled YdAGFdL (1.12 microgram) was dosed with each of four protecting agents: (1) decanted soy flour, <1K MW; (2) decanted and ultrafiltered soy flour, 1K-30K MW; (3) pepsin-treated (FMC ACTI-MOD) soy flour, <30K MW; (4) the potent aminopeptidase inhibitor amastatin (positive control). Blood was collected from a jugular vein cannula at various times post-dosing, and intact YdAGFdL was quantified by a radiometric thin layer chromatography (TLC) method utilizing reverse phase KC-18 TLC plates (Whatman Co.). The TLC plates were developed with 30:70 1-propanol/0.1M phosphat buffer (pH 4.1).

Table VIII presents absolute bioavailabilities from various treatments. The pepsin-treated (FMC ACTI-MOD) soy flour (MW <30K) was particularly effective as a protecting agent against intestinal aminopeptidases, as evidenced by an almost 11-fold increase in % absorbed. The potent aminopeptidase inhibitor amastatin was also effective, demonstrating that the bioavailability of YdAGFdL is partially limited by

degradation by intestinal aminopeptidases. Unroasted soy flour offered no protection to degradation by intestinal aminopeptidases.

Table VIII		
Protecting Agent	n	% YdAGFdL Bioavailability
None (control)	16	1.78 ± 0.46
Decanted soy flour; <1K MW (100 mg)	4	1.74 ± 0.68
Decanted, ultrafiltered soy flour (FMC ACTI- MOD); 1K-30K MW 150mg)	4	2.76 ± 1.43
Pepsin-treated soy flour; <30K MW (100 mg)	4	19.54 ± 13.75
Amastatin (1 mg) (positive control, Sigma Chemical Co.)	6	8.76 ± 4.47
Soy Flour, Unroasted (Sigma) 50 mg	2	1.88 ± 0.67

#### EXAMPLE 16

##### Preparation of Pepsin-Treated Soy Flour, Using Immobilized Pepsin

25 Soy flour (Sigma Chem. Co.) (36 gm) was suspended in 1080 ml water and 120 ml of a 0.1% (w/v) solution of Thimerosol. The suspension was mixed at room temperature for 24 hr, and centrifuged for 1 hr at 3600 rpm. The supernatant was ultrafiltered using a 30K MWCO membrane. The >30K MW fraction was collected, concentrated, and adjusted to pH 2 with 0.5 N HCl. This >30K MW fraction was fed  
30 into an ACTI-MOD spiral reactor module loaded with 8 gm immobilized pepsin (FMC Corp., Pinebrook, NJ). The outflow of the enzyme reactor was ultrafiltered using a 30K MWCO membrane. The <30K MW fraction was saved, and the >30K MW fraction was recirculated through the enzyme reactor. After 2 hr total enzyme treatment and ultrafiltration, the total <30K MW fraction was saved, and was designated "Ultrafiltered,  
35 Pepsin-Treated (<30K) Soy Flour".

-20-

**EXAMPLE 17****Inhibition of Trypsin - Catalyzed Degradation  
of Benzoyl-Arginine-para-Nitroanilide In Vitro**

The following procedure was employed to assess the in vitro inhibitory potency of a protecting agent of this invention vs the trypsin-catalyzed degradation of benzoyl-arginine-para-nitroanilide (BAPNA). Test solutions of trypsin (1.25 ug/ml, 103 BAEE units/ml), BAPNA 0.5 mg/ml, and test inhibitor (0.5 mg/ml) were prepared in a pH 8 TRIS (0.048 M) / CaCl<sub>2</sub> (0.019 M) buffer containing 3.75 ug/ml of bovine serum albumin and incubated at 37°C. Samples were taken at 5 minutes and then at 5 minute intervals up to 40 minutes and quenched with an equal volume of 30% v/v acetic acid preparatory to analysis. Analysis of the decay product of BAPNA hydrolysis, 4-nitroaniline, was carried out using a Perkin-Elmer Lambda 3B UV/Vis Spectrophotometer. Absorbance of the quenched samples was measured at 410 nm. Data were expressed as % inhibition of BAPNA degradation based upon comparison with a control, which contained no inhibitor, as calculated from the following equation:

$$\% \text{ inhibition} = 100\% \times [1 - (S_{rh}/S_o)],$$

where,  $S_{rh}$  is the rate of change of absorbance with time in the presence of inhibitor and  $S_o$  is the rate of change of absorbance with time in the absence of inhibitor.

Percent inhibition was determined using filtered soy flour, 30K - 100K fraction. This lot of processed soy flour was prepared according to the solubilization and ultrafiltration method described in Example 3. The results are given in Table IX and demonstrate that the tested processed protein fraction reduced the trypsin-catalyzed degradation of BAPNA.

**Table IX.** Reduction of trypsin - catalyzed degradation of BAPNA by the 30K - 100K fraction of processed soy flour.

Table IX		
Inhibitor Concentration	Inhibitor Protein Concentration	
(mg/ml)	(mb protein/ml)	% Inhibition
0.5	0.41	73



-21-

EXAMPLE 18Additional fractionation and enzyme treatment procedures

5 The procedures for molecular weight fractionation of proteins and peptides described in Examples 1-8 are varied to produce any desired molecular weight fraction by appropriate choice of ultrafiltration membranes or dialysis membranes. Molecular weight fractionation is also effected by gel chromatography.

Enzymatic treatment, as exemplified in Examples 4-7, is carried out with a single proteolytic enzyme, or with various combinations of proteolytic enzymes, acting  
10 concurrently or sequentially. A variety of proteolytic enzymes are used, including but not limited to trypsin, chymotrypsin, elastase, carboxypeptidase, aminopeptidase, pepsin, and collagenase.

The fractionation and enzymatic treatments of Examples 1-8 are applied to a wide variety of proteinaceous materials of animal or vegetable origin. Such  
15 proteinaceous starting materials include but are not limited to soy flour, soy protein, wheat gluten, almond powder, peanut powder, casein, and fish protein.

EXAMPLE 19

The ability of a protecting agent to dissolve quickly and to begin acting  
20 immediately upon being released *in vivo* is an important factor for the performance of the degradation-reducing agents of this invention. For this purpose, the ability of soy flour and of 30K-100K soy flour, decanted and ultrafiltered, to reduce the degradation of Terlakiren in a dynamic environment were compared *in vitro*. The *in vitro* methodology of Example 8 was followed except the test solution contained only enzyme and  
25 Terlakiren in buffer. Test inhibitor (soy flour or 30K-100K soy flour, decanted and ultrafiltered) was added at a concentration of 0.01 mg/ml without additional mixing, while solution was shaking at speed 5 in a water bath (American Scientific, model # YB531) at 37°C. Sampling was at 19 seconds, 1 minute, then 2 minute intervals until 11 minutes had elapsed, then at 5 minute intervals for a total of 46 minutes.  
30 Quenching, HPLC analysis and data analysis were as in Example 8.

-22-

Test Inhibitor 0.01 mg/ml	$k^*$ (m mol/min)	% Inhibition
Soy flour	$2.96 \times 10^{-4}$	27.1
Soy flour decanted & ultrafiltered 30K-100K	$0.86 \times 10^{-4}$	78.8

10           Although the invention has been described with regard to its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that various changes and modifications as would be obvious to one having ordinary skill in this art may be made without departing from the scope of the invention which is defined in the claims.

15

Claims

We claim:

1. A pharmaceutical composition comprising a protecting agent and a biologically effective amount of a proteolytically-labile therapeutic agent, with the proviso that when said protecting agent is soy flour, said therapeutic agent may not be insulin.
2. The pharmaceutical composition of claim 1 wherein said protecting agent is selected from a protein, a peptide, a purified natural protein, a molecular weight fractionated protein, a solvent-extracted protein, or a partially hydrolyzed protein.
3. The pharmaceutical composition of claim 1 wherein said protecting agent is a partially hydrolyzed protein which has been hydrolyzed by enzymatic means.
4. The pharmaceutical composition of claim 3 wherein said enzymatic means is trypsin, chymotrypsin, elastase, carboxypeptidase, aminopeptidase, pepsin or collagenase.
5. The pharmaceutical composition of claim 1 wherein said protecting agent is a partially hydrolyzed, molecular weight-fractionated protein which has a molecular weight greater than 1000.
6. The pharmaceutical composition of claim 1 wherein said protecting agent is a partially hydrolyzed, molecular weight-fractionated protein which has a molecular weight range of 1000 to 30000.
7. The pharmaceutical composition of claim 1 wherein said protecting agent is soy flour, soy protein, wheat gluten, almond flour, peanut flour, casein or fish protein.
8. The pharmaceutical composition of claim 1 wherein said protecting agent is a protein or molecular weight-fractionated, partially hydrolyzed protein which is derived from naturally occurring protein.
9. The pharmaceutical composition of claim 1 wherein said proteolytically-labile therapeutic agent is calcitonin, prolactin, adrenocorticotropin, thyrotropin, growth hormone, gonadotropic hormone, oxytocin, vasopressin, gastrin, tetragastrin, pentagastrin, glucagon, secretin, pancreozymin, substance P, gonadotropin, immunoglobulin, leuprolide, luteinizing hormone releasing hormone, enkephalin, cholecystokinin, follicle stimulating hormone, interferon, interleukin, thymopentin, endothelin, neurotensin, insulin, insulinotropin, or terlakiren.
10. A method of enhancing bioavailability of a proteolytically-labile therapeutic agent comprising administering said therapeutic agent to a mammal in need

-24-

of said therapeutic agent in combination with a protecting agent in an amount sufficient to enhance the bioavailability of said therapeutic agent, with the proviso that when said protecting agent is soy flour said therapeutic agent may not be insulin.

11. The method of claim 10 wherein said protecting agent is selected from  
5 a protein, a peptide, a purified natural protein, a molecular weight-fractionated protein, a solvent-extracted protein, or a partially hydrolyzed protein.

12. The method of claim 10 wherein said protecting agent is a partially hydrolyzed protein which has been hydrolyzed by enzymatic means.

13. The method of claim 12 wherein said enzymatic means is trypsin,  
10 chymotrypsin, elastase, carboxypeptidase, aminopeptidase, pepsin or collagenase.

14. The method of claim 10 wherein said protecting agent is a partially hydrolyzed protein which has a molecular weight greater than 1000.

15. The method of claim 10 wherein said protecting agent is a partially hydrolyzed protein which has a molecular weight range of 1000 to 30000.

16. The method of claim 10 wherein said protecting agent is protein or a  
15 partially hydrolyzed protein from soy flour, soy protein, wheat gluten, almond flour, peanut flour, casein or fish protein.

17. The method of claim 10 wherein said protecting agent is protein or a partially hydrolyzed protein which is naturally occurring protein.

18. The method of claim 10 wherein said proteolytically-labile therapeutic  
20 agent is calcitonin, prolactin, adrenocorticotropin, thyrotropin, growth hormone, gonadotropic hormone, oxytocin, vasopressin, gastrin, tetragastrin, pentagastrin, glucagon, secretin, pancreozymin, substance P, gonadotropin, immunoglobulin, fibrinogen, leuprolide, luteinizing hormone releasing hormone, enkephalin,  
25 cholecystikinin, follicle stimulating hormone, interferon, interleukin, thymopentin, endothelin, neurotensin, insulin, insulinotropin, or terlakiren.

19. The method of claim 18 wherein said proteolytically-labile therapeutic agent is terlakiren.

20. The pharmaceutical composition of claim 9 wherein said proteolytically-  
30 labile therapeutic agent is terlakiren.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/09336

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K47/42; //C07K15/10		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP,A,0 127 535 (HADASSAH MEDICAL ORGANIZATION) 5 December 1984 cited in the application see page 3, line 21 - page 6, line 25 see claim 2 ---	1-2, 7-11, 16-20
X	US,A,4 774 089 (HARVEY H. ASHMEAD) 27 September 1988 see column 7, line 31 - line 34 see claims 1,5 ---	1-20
X	EP,A,0 341 661 (E.I.DU PONT DE NEMOURS AND COMPANY) 15 November 1989 see the whole document ---	1,9-10, 18-20
	-/--	
<p><sup>10</sup> Special categories of cited documents : <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
03 FEBRUARY 1993	26.02.93	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	FERNANDEZ Y BRA F.	

## III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category <sup>a</sup>	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP,A,0 327 756 (ISF SOCIETA PER AZIONI) 16 August 1989  see page 6, line 51 - line 52 see claims 1-11 ---	1-2, 7-11, 16-20
X	EP,A,0 371 195 (VEB BERLIN-CHEMIE) 6 June 1990  see claims 1-12 ---	1-2, 9-11, 17-20
X	EP,A,0 090 886 (AMERICAN CYANAMID COMPANY) 12 October 1983 see page 1, line 1 - line 6 see claims 1-10 ---	1-20
X	WO,A,9 106 292 (DANOCHMO A.) 16 May 1991  see claims 1-10 ---	1-2, 9-11, 17-20
X	WO,A,9 003 164 (PATRALAN LIMITED) 5 April 1990 cited in the application see page 22, line 26 - page 23, line 24 see page 52 - page 53; example 15 see claim 33 ---	1-2, 9-11, 17-20
A	EP,A,0 266 950 (PFIZER INC) 11 May 1988 cited in the application see the whole document ---	19-20
X	JOURNAL OF CONTROLLED RELEASE vol. 13, no. 2+3, August 1990, NEW YORK pages 213 - 223 VINCENT H.L.LEE 'Protease inhibitors and penetration enhancers as approaches to modify peptide absorption' cited in the application see page 213 - page 215 -----	1-2, 9-11, 17-20

## INTERNATIONAL SEARCH REPORT

ional application No.

PCT/US 92/09336

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 10-19 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9209336  
SA 66672

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 03/02/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0127535	05-12-84	CA-A- 1223200	23-06-87
		JP-A- 60069028	19-04-85
		US-A- 4579730	01-04-86
US-A-4774089	27-09-88	None	
EP-A-0341661	15-11-89	AU-B- 616968	14-11-91
		AU-A- 3468289	16-11-89
		JP-A- 1319428	25-12-89
EP-A-0327756	16-08-89	GB-A, B 2212062	19-07-89
		BE-A- 1002333	18-12-90
		FR-A- 2623090	19-05-89
EP-A-0371195	06-06-90	JP-A- 3047114	28-02-91
EP-A-0090886	12-10-83	US-A- 4537769	27-08-85
		CA-A- 1213215	28-10-86
		DE-A- 3278344	26-05-88
		JP-A- 58183628	26-10-83
WO-A-9106292	16-05-91	AU-A- 6632490	31-05-91
		EP-A- 0498824	19-08-92
WO-A-9003164	05-04-90	AU-B- 625498	16-07-92
		AU-A- 4243289	05-04-90
		AU-A- 4341789	18-04-90
		EP-A- 0366277	02-05-90
		JP-A- 2218609	31-08-90
EP-A-0266950	11-05-88	AU-B- 585180	08-06-89
		AU-A- 8054187	05-05-88
		JP-A- 63183551	28-07-88
		SU-A- 1706391	15-01-92
		US-A- 4814342	21-03-89
		US-A- 4935405	19-06-90
		US-A- 5034376	23-07-91